ImmuPharma progresses P140 clinical programme with FDA
12th Apr 2023 14:13
(Sharecast News) - Drug discovery and development company ImmuPharma announced positive progress in its late-stage P140 clinical programme on Tuesday, for patients with chronic idiopathic demyelinating polyneuropathy (CIDP), a rare neurological disease with high medical need.
Read moreImmuPharma upbeat after meeting with US partner Avion
11th Nov 2022 13:04
(Sharecast News) - Drug discovery and development specialist ImmuPharma updated the market on a recent meeting in Atlanta with its United States partner Avion Pharmaceuticals on Friday, for strategic discussions around its 'Lupuzor' clinical programme.
Read moreImmuPharma's US partner receives FDA response on Lupuzor
14th Sep 2022 13:51
(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced on Wednesday that its US partner for 'Lupuzor', Avion Pharmaceuticals, has received a written response from the Food and Drug Administration (FDA).
Read moreImmuPharma making final preparations for Lupuzor phase 3 trial
4th May 2022 13:03
(Sharecast News) - Specialist drug discovery and development company ImmuPharma said on Wednesday that final preparations were now underway to progress 'Lupuzor' into its new, optimised international phase 3 trial in lupus patients.
Read moreImmuPharma surges on success in latest trial of lupus treatment
13th Apr 2022 13:54
(Sharecast News) - Specialist drug discovery and development company ImmuPharma reported positive data from its 'Lupuzor' pharmacokinetic study on Wednesday, as part of the new, optimised international third phase trial in lupus patients.
Read moreImmuPharma updates plan for trials of lupus treatment Lupuzor
7th Feb 2022 13:13
(Sharecast News) - Drug discovery and development specialist ImmuPharma updated the market on the pharmacokinetic study of 'Lupuzor' on Monday, as part of the new, optimised international phase 3 trial of Lupuzor in lupus patients.
Read moreImmuPharma raises £3.55m to fund research pipeline
20th Dec 2021 11:22
(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced subscriptions and a placing to raise £3.55m on Monday, to fund its research and development pipeline as well as general working capital.
Read moreImmuPharma signs two-year collaboration deal with Imperial College
29th Nov 2021 13:32
(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced on Monday that it has signed a two-year collaboration agreement with Imperial College London.
Read moreImmuPharma reports 'significant' progress since restructure
18th Nov 2021 15:16
(Sharecast News) - Specialist drug discovery and development company ImmuPharma reported "significant" positive progress on Thursday, following major changes to its board and a restructuring of senior management in August.
Read moreFDA gives ImmuPharma go-ahead for pharmacokinetic study
12th Aug 2021 13:02
(Sharecast News) - Specialist drug discovery and development company ImmuPharma said on Thursday that the United States Food and Drug Administration (FDA) has approved the start of the pharmacokinetic study as part of its new, "optimised" international phase 3 trial of 'Lupuzor'.
Read moreImmuPharma clarifies next steps for phase 3 Lupuzor trial
9th Feb 2021 14:13
(Sharecast News) - Specialist drug discovery and development company ImmuPharma updated the market on the new optimised international phase 3 trial of 'Lupuzor' in the potentially life-threatening auto-immune disease systemic lupus erythematosus (SLE) on Tuesday.
Read moreImmuPharma gets December date for FDA meeting
20th Nov 2020 12:15
(Sharecast News) - Specialist drug discovery and development company ImmuPharma updated the market on the new optimised international phase 3 trial of 'Lupuzor' in systemic lupus erythematosus (SLE) on Friday, reporting that the US Food & Drug Administration (FDA) has now confirmed the date of 4 December for a Type 'A' Meeting Request.
Read moreImmuPharma confirms continued FDA delays for Lupuzor
11th Sep 2020 12:17
(Sharecast News) - Specialist drug discovery and development company ImmuPharma on its special protocol assessment (SPA) submission to the US Food and Drug Administration (FDA) for the phase 3 trial of 'Lupuzor' in lupus patients.
Read moreImmupharma raises £6.5m in oversubscribed placing
2nd Sep 2020 09:25
(Sharecast News) - Drug discovery and development firm Immupharma has raised £6.5m, before fees, via an oversubscribed placing of 59.09m ordinary shares.
Read moreImmuPharma clears 'important' regulatory hurdle for Lupuzor trial
27th Jul 2020 15:15
(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced what it called "an important regulatory milestone" on Monday, in preparation for the new optimised international phase 3 trial of 'Lupuzor' for the autoimmune disease systemic lupus erythematosus.
Read more